EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes

Denise A Yardley

International Journal of Breast Cancer · 2013 · 2013 · 1-15

DOI: 10.1155/2013/137414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Breast Cancer, 2013. Verfasst von Denise A Yardley. Beteiligte Einrichtung: Breast Cancer Research, Sarah Cannon Research Institute, 250 25th Avenue North, Suite 110, Nashville, TN 37203, USA. Die Arbeit wurde bisher 180-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Bristol-Myers Squibb.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to cancer chemotherapy is a common phenomenon especially in metastatic breast cancer (MBC), a setting in which patients typically have had exposure to multiple lines of prior therapy. The subsequent development of drug resistance can result in rapid disease progression during or shortly after completion of treatment. Moreover, cross-class multidrug resistance limits patient treatment choices, particularly in a setting where treatments options are few. One attempt to minimize the impact of drug resistance has been the concurrent use of two or more chemotherapy agents with unrelated mechanisms of action and differing modes of drug resistance, with the intent of blocking the development of multiple intracellular escape pathways essential for tumor survival. Within the past decade, an array of mechanistically diverse agents has augmented the list of combination regimens that may be both synergistic and efficacious in pretreated MBC. The aim of this paper is to review mechanisms of resistance to common chemotherapy agents and to consider current combination treatment options for heavily pretreated and/or drug-resistant patients with MBC.

Autor:innen und Institutionen

  • Breast Cancer Research, Sarah Cannon Research Institute, 250 25th Avenue North, Suite 110, Nashville, TN 37203, USA.

Förderung

  • Bristol-Myers Squibb

Zitieren

APA

Yardley, D. A. (2013). Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes. International Journal of Breast Cancer, 2013, 1-15. https://doi.org/10.1155/2013/137414

Vancouver

Yardley DA. Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes. International Journal of Breast Cancer. 2013;2013:1-15. doi:10.1155/2013/137414

BibTeX
@article{Yardley2013,
  author = {Yardley, Denise A},
  title = {Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes},
  journal = {International Journal of Breast Cancer},
  year = {2013},
  volume = {2013},
  pages = {1--15},
  doi = {10.1155/2013/137414}
}
Kostenlos starten →